A Comparative Study Of Lamps And Ykl-40 Tissue Expression In Glial Tumors

Abstract

INTRODUCTION: YKL-40 is a glycoprotein believed potentially to be a marker of various pathological processes. High levels of YKL-40 have been found in cancer and chronic infl ammatory diseases. The function of the glycoprotein is not completely known yet. A possible involvement in angiogenesis and tumor aggressiveness is supposed. Lysosome-associated membrane glycoproteins (LAMP) 1 and 2 are highly conserved proteins with still undefi ned biological functions. There is evidence that they are implicated in autophagy, angiogenesis and tissue remodeling. AIM: The aim of the present study was to investigate the potential relationship between the tissue expression of YKL-40, LAMP-1 and LAMP-2 in glial tumors. MATERIAL AND METHODS: LAMPs and YKL-40 expression was determined by immunohistochemistry in 36 glial tumors. A morphometric analysis of the intensity of tissue expression was performed with the Quick-photo Micro 2.3. system. Area (μm), perimeter (μm), and expression level (%) of the three glycoproteins were calculated. RESULTS: LAMPs were found on cell membranes of glial and endothelial cells, while YKL-40 was detected in the cytoplasm of these cells. Intensive immunohistochemical reaction was present in tumor cells. LAMP-2 showed a more intensive staining compared to LAMP-1. CONCLUSION: We present the fi rst comparative study of YKL-40 and LAMPs in astroglial tumors. The relationship between the expression of the three glycoconjugates indicates a possible participation in the processes of angiogenesis and tissue remodeling during tumor development

Chitinase-3-like Protein 1 (YKL-40) Expression in Squamous Cell Skin Cancer

“…However, IHC reaction did not correlate with any of the clinical parameters, which is in accordance with other reports (22). To the best of our knowledge this is the first study on the expression of YKL-40 in non-melanoma skin cancers.…”

“…The studies available so far have clearly shown that many other malignant cells or cell lines express and release this protein. Positive YKL-40 expression has been reported in breast, colon, lung, prostate, thyroid, ovarian, hepatocellular, and renal cancers, as well as in glial and chondroid tumors, melanoma, osteosarcoma and soft tissue sarcomas (14,(19)(20)(21)(22)(26)(27)(28)(29)(30). It was also found that squamous cell carcinomas developed within the mucous membranes of larynx, pharynx, oral cavity and esophagus show YKL-40 expression (23,24).…”

“…Moreover, YKL-40 expression has been shown in the cells of many malignancies, such as melanoma, renal cell cancer, endometrial cancer, breast cancer, glial tumors, osteosarcoma, soft tissue sarcomas or squamous cell carcinomas of head, neck and esophagus (14,17,(19)(20)(21)(22)(23)(24). It has been even suggested that YKL-40 can serve as a new target for anticancer therapy (9,25).…”

High VEGFA Expression Is Associated with Improved Progression-Free Survival after Bevacizumab Treatment in Recurrent Glioblastoma

“…Our results showed YKL40 to be highly expressed in tumor cells, consistent with previous reports [ 36 , 37 , 38 ]. Inflammatory cells also showed some expression of YKL40, which has been previously attributed to the presence of tumor-infiltrating macrophages [ 22 , 64 ].…”

“…In our evaluation of YKL40, 28 out of 55 (50.9%) samples had a low percentage of positive YKL40 tumor cells (<25%), while 12 out of 55 (21.8%) had a high percentage (>75%) ( Table 4 ). The majority of YKL40 expression (70.9%) was observed to be strong (and cytoplasmatic) ( Figure 1 g,h), as has been previously reported [ 36 , 37 , 38 ]. Moreover, YKL40 expression was observed, albeit to a lesser extent, in inflammatory cells.…”